Scottish partnership to boost kidney disease research
A new partnership between NHS Scotland, AstraZeneca and the Universities of Dundee and Glasgow hopes to accelerate research into treating chronic kidney disease.
The partners will work together on new medicines to slow the progression of chronic kidney disease, reducing the risk that patients might need dialysis or kidney transplantation.
The partnership aims to facilitate the development of new treatments to treat chronic kidney disease, build infrastructure and enhance expertise in renal clinical trial delivery in Scotland.
Cabinet Secretary for Health and Social Care, Neil Gray, said: “This project’s ‘triple helix’ approach is a shining example of how collaboration between the NHS, Scottish Government, academia and industry can accelerate health studies. As we navigate the complex issue of chronic kidney disease, our commitment to patient-centred research remains unwavering.
“Together we can advance targeted studies into medicines that slow progression of the disease and reduce the need for dialysis or transplantation, strengthen our workforce through dedicated research fellowships and specialised training, provide greater opportunities for patients, and enable Scotland to attract and deliver more innovative trials.”
Tom Keith-Roach, AstraZeneca UK President, added: “Scotland is setting a bold ambition to change the trajectory of chronic kidney disease. We are thrilled to invest in a partnership with the University of Glasgow, the University of Dundee, and the Scottish Government to speed up the study of three potential new combination medicines to treat this disease.
“The triple helix of industry, academia and NHS Scotland is a powerful force with the potential to transform care and outcomes for people. Furthermore, we believe Scotland is well placed to collaborate with AstraZeneca to shape our research on the world stage across a number of disease areas and attract investment to the country’s thriving life science sector.”
Diana Spencer, Senior Digital Content Editor, DDW
